Next Article in Journal
Aplysin Sensitizes Cancer Cells to TRAIL by Suppressing P38 MAPK/Survivin Pathway
Next Article in Special Issue
Modification of Marine Natural Product Ningalin B and SAR Study Lead to Potent P-Glycoprotein Inhibitors
Previous Article in Journal
A Feedback Mechanism to Control Apoptosis Occurs in the Digestive Gland of the Oyster Crassostrea gigas Exposed to the Paralytic Shellfish Toxins Producer Alexandrium catenella
Previous Article in Special Issue
Tricyclic Guanidine Alkaloids from the Marine Sponge Acanthella cavernosa that Stabilize the Tumor Suppressor PDCD4
Open AccessArticle

Chronic Toxicity Study of Neosaxitoxin in Rats

Molecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, Medical School, University of Chile, Independencia 1027, 8380453 Santiago, Chile
School of Medicine, ICBM, Medical School, Universidad de Chile, Independencia 1027, 8380453 Santiago, Chile
Anesthesia Department, Brigham and Woman's Hospital, Harvard University, 75 Francis Street, Boston, MA 02115, USA
Author to whom correspondence should be addressed.
Mar. Drugs 2014, 12(9), 5055-5071;
Received: 29 January 2014 / Revised: 6 June 2014 / Accepted: 7 July 2014 / Published: 25 September 2014
(This article belongs to the Special Issue Alkaloid Analogs)
Neosaxitoxin (NeoSTX) is a specific reversible blocker of voltage gated sodium channels on excitable cells. In the last decade, it has been tested in a number of interesting clinical trials, however there is still little information available on mammalian toxicity. Rats were treated for 12 weeks with doses of 1, 3 or 6 μg/kg of subcutaneous NeoSTX. At weeks 12 and 17, animals were sacrificed and blood samples collected for hematological and biochemical analysis. Organs were harvested for weight determination and histopathological assessments. The lowest acute toxicity via the intraperitoneal (ip) route was (30.35 μg/kg) and there was no significant difference between intramuscular and subcutaneous routes (11.4 and 12.41 μg/kg). The NeoSTX adiministration did not produce lethality at week 12 and after five weeks of suspension. NeoSTX 6 μg/kg ip produced reductions (p < 0.05) in body weight and food intake, and increased blood level of total and direct bilirubin, GGT and SGOT at week 12; all of these were reversed in the recovery period. NeoSTX 1 and 3 μg/kg ip did not show significant changes with the control group. Histopathological presentations were normal in all groups. This study revealed that NeoSTX is safe in vivo, giving a reliable security margin for its use like a local anesthetic. View Full-Text
Keywords: neosaxitoxin; marine toxin; chronic toxicity; acute toxicity neosaxitoxin; marine toxin; chronic toxicity; acute toxicity
Show Figures

Graphical abstract

MDPI and ACS Style

Zepeda, R.J.; Candiracci, M.; Lobos, N.; Lux, S.; Miranda, H.F. Chronic Toxicity Study of Neosaxitoxin in Rats. Mar. Drugs 2014, 12, 5055-5071.

AMA Style

Zepeda RJ, Candiracci M, Lobos N, Lux S, Miranda HF. Chronic Toxicity Study of Neosaxitoxin in Rats. Marine Drugs. 2014; 12(9):5055-5071.

Chicago/Turabian Style

Zepeda, Ramiro J.; Candiracci, Manila; Lobos, Nicolas; Lux, Sebastian; Miranda, Hugo F. 2014. "Chronic Toxicity Study of Neosaxitoxin in Rats" Mar. Drugs 12, no. 9: 5055-5071.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop